Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | CDC25B | P30305 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | SNCA | P37840 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21316062 | 0.64 | CDC25B (0.32) | IDO1MAOAMAOBCDC25BAKT1 | |
| SCHEMBL31689772 | 0.59 | — | — | |
| SCHEMBL18198918 | 0.57 | — | — | |
| SCHEMBL7102907 | 0.55 | — | — | |
| SCHEMBL18198919 | 0.55 | — | — | |
| SCHEMBL223037 | 0.55 | CDC25B (0.50) | MEN1USP2ALDH1A1LMNATP53 | |
| SCHEMBL2059663 | 0.52 | — | — | |
| SCHEMBL1493690 | 0.52 | ERBB2 (0.31) | CYP1A2MAOA | |
| Naphthoquinone SCHEMBL11359780 | 0.51 | IDO1 (1.00) | MEN1USP2ALDH1A1LMNATP53 | |
| Naphthoquinone SCHEMBL29354680 | 0.51 | IDO1 (1.00) | MEN1USP2ALDH1A1LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2207801-B1 | METHODS OF INHIBITING VIRAL INFECTION | FUNCTIONAL GENETICS INC (US) | 2013-04-17 | — | — | EP | disclosed |
| US-8207209-B2 | Methods of inhibiting viral infection | FUNCTIONAL GENETICS, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-20090170890-A1 | METHOHDS OF INHIBITING VIRAL INFECTION | FUNCTIONAL GENETICS, INC. (US) | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170890-A1 | METHOHDS OF INHIBITING VIRAL INFECTION | CASP8, CASP1, CASP3 | MEN1 2405/4885USP2 298/4885ALDH1A1 2709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.